BTK inhibitors kill mantle cell lymphoma by inducing ferroptosis, and resistant tumours use BRG1 to shut that death pathway down.

BTK inhibitors changed the treatment of several blood cancers. By blocking Bruton’s tyrosine kinase, a node in the signalling that B cells use to stay alive and divide, they produce responses in lymphomas that previously had few options — and then, after a year or two, the responses stop.

A study in Nature Communications from Weill Cornell Medicine proposes an explanation for how that happens in mantle cell lymphoma, and the mechanism is not the one resistance research usually finds.

The drugs turn out to kill these cells by inducing ferroptosis — an iron-dependent form of cell death — and resistant tumours survive by switching that pathway off. The gene doing the switching is BRG1, a chromatin remodeller.

A death the drug was not designed to cause

Ferroptosis was only described in 2012, which is recent enough that it was not on anyone’s mind when BTK inhibitors were developed. It works by lipid peroxidation: iron catalyses the oxidation of fats in cell membranes until the membrane fails, and a cell dies from a chemical chain reaction rather than from the orderly programme of apoptosis.

That the drug kills through this route is the study’s first claim, and the evidence comes from patient material. In samples from patients who responded to BTK inhibitors, treatment induced ferroptosis. In samples from patients who had stopped responding, it did not.

This is a useful kind of evidence because it is not a cell line. The distinction tracks clinical response in the tissue of people whose outcomes are known, which makes the pathway a plausible mechanism of action rather than something observed in culture.

What BRG1 does

“We found that the chromatin remodeler BRG1 rewires gene expression to protect lymphoma cells from ferroptosis,” said Soo-Yeon Hwang, the study’s first author and a postdoctoral associate in the Paik Lab at Weill Cornell Medicine.

A chromatin remodeller is machinery that repositions nucleosomes, changing which stretches of DNA are accessible to be read. BRG1 — also known as SMARCA4 — is the ATPase at the core of the SWI/SNF complex, one of the most frequently altered systems in human cancer. It does not regulate one gene; it changes what a cell’s genome makes available.

The specific effect here is chemical. BRG1 activity reduces reactive oxygen species and free iron, which are the two main ingredients ferroptosis requires. A cell that has lowered both is harder to kill by lipid peroxidation, and the drug loses its mechanism without anything happening to BTK itself.

That last point is what makes the finding interesting. Most acquired resistance to a targeted drug involves the target — a mutation in the binding site, a bypass pathway reactivating the same signalling. Resistance that works by hardening the cell against the death the drug triggers is a different category, and it would not be detected by sequencing the target.

The ambiguity in “abnormal activity”

One thing the release does not resolve deserves stating, because it affects what the finding means.

BRG1 is described both as frequently mutated in resistant mantle cell lymphoma and as protecting cells through its activity. Those two descriptions pull in opposite directions. SMARCA4 alterations in most cancers are inactivating, and the gene is generally discussed as a tumour suppressor whose loss is oncogenic. A mechanism in which BRG1 activity protects cells requires the alterations to be activating, or to change what BRG1 targets rather than whether it works.

The release says only that the resistance mechanism involves abnormal activity of the protein, which is compatible with either. For a result whose therapeutic proposal is a BRG1 inhibitor, whether the relevant alterations increase or redirect BRG1 function is not a detail.

The combination

The treatment proposal follows directly. In animal tests, adding a BRG1 inhibitor markedly improved a BTK inhibitor’s antitumour activity and extended survival.

“These findings reveal a potential new therapeutic vulnerability that could be targeted to overcome drug resistance,” said Jihye Paik, co-senior author and an associate professor of pathology and laboratory medicine at Weill Cornell Medicine and a member of the Sandra and Edward Meyer Cancer Center. The other co-senior author is Hongwu Zheng, assistant professor of research in pathology and laboratory medicine.

Restoring sensitivity to a drug a patient has already stopped responding to is the most valuable thing a resistance mechanism can offer, because it reuses a treatment whose dosing and side effects are already understood. It is also the step where this result is furthest from a clinic.

What is not here

The release reports no quantitative results at all. There is no number of patient samples, no survival figures from the animal experiments, no measure of how much the combination improved on the BTK inhibitor alone, and no effect size for the ferroptosis difference between responders and non-responders. “Markedly improved” and “extended survival” are the entire quantitative content.

It also gives neither the paper’s title nor a DOI, which is unusual for a journal release and makes the paper harder for a reader to find than it should be.

The pharmacology is the other open question. BRG1 inhibitors exist as research compounds and early clinical candidates, and the SWI/SNF complex is essential in normal cells — which is the standard difficulty with drugging chromatin machinery, since the therapeutic window between a tumour that needs it and a tissue that also needs it can be narrow. Nothing in the release addresses toxicity.

What the work establishes, on the evidence described, is a mechanism with a matching intervention that worked in mice. Mantle cell lymphoma is an aggressive disease that relapses reliably, and the patients who have exhausted BTK inhibitors are the ones with fewest options, which is reason enough to take a resistance mechanism seriously while being clear that no part of this has been tested in a person.

The research was funded by the National Cancer Institute (CA214274 and CA276349), the Leukemia and Lymphoma Society’s Mantle Cell Lymphoma Research Initiative (MCL7001-18) and the National Research Foundation of Korea (RS-2024-00411768). The paper was published on 2 July 2026; the release does not give the full author list or state any conflicts of interest.

---

Notes

1. Hwang, S.-Y., Paik, J., Zheng, H., et al. Nature Communications, 2026. The release does not state the paper’s title or a DOI.
2. Weill Cornell Medicine. “A promising solution to a cancer drug resistance problem.” EurekAlert!, 4 August 2026. https://www.eurekalert.org/news-releases/1138791.

NTU Singapore